|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,670 GBX | +1.03% |
|
+1.86% | +15.16% |
| 01:29pm | GSK : UBS reaffirms its Buy rating | ZD |
| 08:52am | Hipgnosis Songs Fund backs new Blackstone bid | AN |
Oct 9 (Reuters) - GSK, on Monday, announced an exclusive partnership with China's Chongqing Zhifei Biological Products (Zhifei) for its shingles vaccine.
Zhifei will purchase worth 2.5 billion pounds ($3.05 billion) of the vaccine, named 'Shingrix', over an initial three-year period, GSK said. ($1 = 0.8193 pounds) (Reporting by Eva Mathews in Bengaluru; Editing by Savio D'Souza)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 2,686 PTS | +0.86% | +2.29% | - | ||
| 1,670 GBX | +1.03% | +1.86% | 84.13B | ||
| 35.7 CNY | +2.50% | -11.83% | 11.51B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +15.16% | 84.13B | |
| +25.92% | 661B | |
| +26.74% | 566B | |
| -6.64% | 352B | |
| +18.76% | 332B | |
| +3.35% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.36% | 145B |
GSK PLC 
